Cadila launches anti-obesity drug Slimona

New Delhi, May 15 (UNI) Cadila Healthcare Ltd today said it has launched Slimona, a new generation anti-obesity drug in India.

The drug, in a tablet form of strength 20 mg, has been approved for the treatment of obese patients with associated risk factors, such as type II diabetes or dyslipidemia, a company sattement said.

It is priced at a rate of Rs 5.50 per tablet, making it economical to a wide patient group.

''The price of Slimona has been thoughtfully fixed to benefit the large patient population in all classes. We will harness the full thrust of the Zydus marketing teams to ensure that this vitally needed drug is available to doctors across the country - even in smaller cities and towns,'' company's Senior Vipe-President (BU-7) Ashok Bhatia said.

The company currently markets products in cardiology, diabetology and neurology segments.

UNI